Tag: RSH
Shareholders back Respiri in heavily oversubscribed share purchase plan
Respiri (ASX: RSH) has topped up its cash reserves with $3.14 million after receiving “significant oversubscriptions” in a recent share purchase plan.
The company launched the share purchase plan l...
Respiri strikes telehealth deal with Aussie start-up to improve respiratory care for asthma patients
Respiratory health management company Respiri (ASX: RSH) has entered into commercial discussions with Australian start-up Practice Innovators International Pte Ltd with a view to launching an integrat...
Respiri expands wheezo into telehealth market with Phenix partnership
Respiri (ASX: RSH) has expanded the market for its wheezo technology after announcing a partnership with Phenix Health.
The parties have inked a joint development agreement which will involve integ...
Respiri experiences requests for wheezo devices to monitor COVID-19 patients in China
Respiratory focused SaaS company Respiri (ASX: RSH) has experienced inbound demand for its wheezo technology from three Chinese hospitals relating to monitoring patients with coronavirus COVID19...
Respiri’s Wheezo product approved for sale following CE Mark and TGA registration
Healthcare technology developer Respiri (ASX: RSH) has revealed that the company has received the highly coveted CE Mark and TGA approval to list its Wheezo product on the Australian Therapeutics Good...
Appointment of professor Bruce Thompson provides Respiri clinical credibility
Bruce Thompson has been appointed as chair of Respiri’s (ASX: RSH) Australian medical and scientific Advisory board and product portfolio development lead.
Bruce Thompson is Professor of Allergy, I...
Respiri appoints SRX Global to manufacture wheeze and asthma sensor
Respiri (ASX: RSH) has ticked off another key milestone – a manufacturing agreement with SRX Global, to produce its next generation breath and asthma wheeze detection sensor.
The sensor is the hard...
Respiri’s wheeze monitoring device to improve asthma management
Healthcare technology developer Respiri (ASX: RSH) is in the final stages of commercialising its asthma monitoring product called AirSonea.
It will be a major boost for asthma sufferers worldwide, ...
